Developing diagnostic criteria in Waldenstrom's macroglobulinemia
- PMID: 12720135
- DOI: 10.1053/sonc.2003.50069
Developing diagnostic criteria in Waldenstrom's macroglobulinemia
Abstract
Waldenstrom's macroglobulinemia (WM) is a poorly characterized B-cell lymphoproliferative disorder. There are a relatively limited number of detailed clinicopathological assessments, while the majority of clinical trials have been nonrandomized, single-institution phase II studies. Unfortunately progress in this disorder has been hindered by a lack of universally accepted diagnostic criteria. It is clear that criteria incorporating clinical, morphological, immunophenotypic, and, ultimately, genotypic parameters are needed for future clinical trails. Following a detailed clinicopathological assessment of 111 patients and a review of the published literature the following diagnostic criteria were proposed for WM: IgM monoclonal gammopathy of any concentration, bone marrow infiltration by small lymphocytes, plasmacytoid cells and plasma cells in a diffuse, interstitial or nodular pattern, and a surface Ig(+)CD19(+)CD20(+)CD5(-)CD10(-)CD23(-) immunophenotype.
Copyright 2003 Elsevier Inc. All rights reserved.
Similar articles
-
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.Semin Oncol. 2003 Apr;30(2):110-5. doi: 10.1053/sonc.2003.50082. Semin Oncol. 2003. PMID: 12720118 Review.
-
Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells.Semin Oncol. 2003 Apr;30(2):182-6. doi: 10.1053/sonc.2003.50073. Semin Oncol. 2003. PMID: 12720133
-
Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors.Am J Clin Pathol. 2001 Sep;116(3):420-8. doi: 10.1309/4LCN-JMPG-5U71-UWQB. Am J Clin Pathol. 2001. PMID: 11554171
-
Immunophenotypic analysis of Waldenstrom's macroglobulinemia.Semin Oncol. 2003 Apr;30(2):187-95. doi: 10.1053/sonc.2003.50074. Semin Oncol. 2003. PMID: 12720134
-
Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity?Clin Lymphoma. 2005 Mar;5(4):220-4. doi: 10.3816/clm.2005.n.003. Clin Lymphoma. 2005. PMID: 15794852 Review.
Cited by
-
Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.Clin Adv Hematol Oncol. 2009 Oct;7(10):677-81, 687-90. Clin Adv Hematol Oncol. 2009. PMID: 20040909 Free PMC article. Review.
-
Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities.Mod Pathol. 2012 May;25(5):651-60. doi: 10.1038/modpathol.2011.213. Epub 2012 Feb 3. Mod Pathol. 2012. PMID: 22301699 Free PMC article.
-
Minimal residual disease status improved the response evaluation in patients with Waldenström's macroglobulinemia.Front Immunol. 2023 May 10;14:1171539. doi: 10.3389/fimmu.2023.1171539. eCollection 2023. Front Immunol. 2023. PMID: 37234167 Free PMC article.
-
Treatment of Waldenstrom's Macroglobulinemia.Curr Treat Options Oncol. 2007 Apr;8(2):144-53. doi: 10.1007/s11864-007-0016-2. Curr Treat Options Oncol. 2007. PMID: 17634838 Review.
-
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.Lancet Haematol. 2017 Jan;4(1):e24-e34. doi: 10.1016/S2352-3026(16)30166-1. Epub 2016 Dec 1. Lancet Haematol. 2017. PMID: 27914971 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources